Direct compression of etilefrine HCl (C10H15NO2·HCl) in low-dose tablet manufacture is driven by segregation control between the API and excipient carriers. The hydrochloride salt is freely water-soluble; when the unit dose is in the 5–10 mg range, the API fraction typically represents less than 10% w/w of a 100–200 mg tablet core. Under these constraints, particle size distribution is confirmed by Ph. Eur. 2.9.31 or USP <429>. The API is pre-screened through a 500 µm stainless steel sieve, then diluted in at least three stages with lactose monohydrate and microcrystalline cellulose in a tumble blender equipped with an intensifier bar. Lubrication with magnesium stearate is held at 0.5–1.0% w/w with a total lubrication time not exceeding 5 min, because over-lubrication reduces tensile strength and delays disintegration. Compression is performed on a rotary tablet press with precompression force between 4 kN and 8 kN and main compression force between 10 kN and 20 kN, using 7–9 mm round tooling with chromium-plated punch faces. In-process limits are established for average hardness, mass uniformity per USP <905> or Ph. Eur. 2.9.40, friability according to USP <1216> or Ph. Eur. 2.9.7, and dissolution by USP <711>. Environmental RH must be maintained below 45% during blending and compression; at higher moisture levels, the water-soluble API can bind to punch faces and cause sticking, picking, and weight variation. Dust extraction at the compression turret and interlocked metal detection upstream of the tablet press are required for commercial production. The API is released against the current Ph. Eur. monograph and, where applicable, the USP or JP monograph, with identity by infrared spectroscopy and chloride test, assay by HPLC, water content by Ph. Eur. 2.5.12 or USP <921>, and residue on ignition.

Why Does Wet Granulation Reduce Segregation in Low-Dose Etilefrine HCl Tablets?

Wet granulation reduces segregation because the API is incorporated into a fixed granule network, eliminating the free-flowing powder fraction most prone to particle size separation. However, the water solubility of etilefrine HCl introduces a drying-phase migration risk. In high-shear granulation, the dry blend is charged into a top-driven high-shear granulator and mixed with a binder solution of polyvinylpyrrolidone K30 at 5–8% w/w solids, added to reach a dry binder content of 2–5% w/w. The endpoint is determined by impeller torque and wet mass consistency rather than fixed time; impeller speeds are typically in the 150–300 rpm range, with a chopper speed near 1500–3000 rpm. The wet mass is wet-milled through a 1.5–2.0 mm screen and transferred to a fluid-bed dryer. Inlet air temperature is controlled at 50–65°C until loss on drying reaches 1.5–2.5% w/w, after which the dried granules are dry-milled through a 0.8–1.0 mm screen. Because the API is freely water-soluble, unbound water during drying can carry etilefrine HCl to the granule surface, creating intra-granule assay variation and dissolution variability. This migration is controlled by reducing initial water content, using shorter wet massing time, and avoiding high early-phase drying rates that exceed the moisture removal capacity of the granule surface. Lactose monohydrate, if retained, must be justified by forced degradation data because the secondary amine can participate in Maillard-type reactions with reducing sugars under heat and moisture; where such data show unacceptable adduct formation, mannitol or dibasic calcium phosphate anhydrous is substituted. Lubricated granules are compressed as described previously; dissolution testing under USP <711> with pH conditions and paddle speed specified in the approved regulatory dossier is used to confirm that granule strength does not delay release. Granule particle size is monitored by sieve analysis, and fines below 100 µm are limited because they can reintroduce segregation at the press hopper.

In capsule filling suites operating at controlled relative humidity, encapsulation of etilefrine HCl usually requires a granulated intermediate rather than a direct powder blend when the Carr index exceeds 25% or the Hausner ratio exceeds 1.35. Capsule formulations in the 5–10 mg dose range commonly use fill weights between 90 mg and 150 mg in size 3 two-piece capsules, with lactose monohydrate or mannitol as the primary diluent and pregelatinized starch or microcrystalline cellulose as the dry binder. The granulated fill is lubricated with 0.5–1.0% w/w magnesium stearate and encapsulated on a tamping pin or dosator-type capsule filler. Fill weight and closure are verified at periodic intervals during the run; average fill weight and weight variation are assessed per USP <905> or Ph. Eur. 2.9.40, while the filled capsules are tested for disintegration in USP <701> and dissolution in USP <711>. Hard gelatin capsule shells are typically stored at 35–45% RH, with shell moisture between 13% and 16% w/w; HPMC shells may require lower moisture ranges due to their different equilibrium moisture profile. If the granule fill absorbs water from the shell, the powder may become tacky and cause incomplete capsule ejection or denting. For this reason, the filling suite is held at 40–45% RH, and the granulated intermediate is equilibrated before filling. Capsule shells containing the API should not be exposed to alkaline impurities or strongly hygroscopic silica exceeding the formulation target, because localized pH shifts can alter the salt form and reduce dissolution performance. Content uniformity is confirmed on stratified samples from the beginning, middle, and end of the filling run to detect blend segregation or hopper depletion effects.

When Unit-Dose Granules Are Dispersed in Water Before Oral Administration

When unit-dose granules are intended for dispersion in water before oral administration, the formulation must balance rapid wetting, dose uniformity, and protection from moisture. Etilefrine HCl granules for sachets or stick packs are commonly produced by high-shear granulation followed by fluid-bed drying, with a target granule size range of 150–850 µm. Fines below 100 µm are minimized to reduce dust and segregation during filling. The sachet fill weight is typically 1–2 g per unit dose, with the API dose in the 5–10 mg range. Mannitol, sorbitol, and low-substituted hydroxypropyl cellulose are used to promote dispersion; sodium saccharin or sucralose is included for taste masking, and citric acid may be used in small amounts to adjust the local pH of the dispersed liquid. However, effervescent matrices containing sodium bicarbonate are generally avoided because the resulting pH elevation can convert etilefrine HCl to its less water-soluble free base, leading to precipitation and reduced dose delivery. Dispersion testing is performed in 50 mL water at 20–25°C, with the acceptance criterion that the granule mass disperses within 30–90 s without agglomerates remaining on the vessel bottom under gentle stirring. Moisture content is controlled to less than 2.0% w/w, because higher moisture can induce caking in the sachet and accelerate hydrolysis. Packaging uses a polyester/aluminum/linear low-density polyethylene laminate with low water vapour transmission; seal integrity is verified according to ASTM F2054 or equivalent burst/peel test methods. Delivery dose uniformity is tested by Ph. Eur. 2.9.40 or USP <905>, dissolution by USP <711>, and non-sterile microbial limits by USP <61> and USP <62> or Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13.

Because etilefrine HCl is freely soluble in aqueous media, oral liquid formulations are prepared as clear solutions with the pH controlled below the point at which free-base precipitation occurs. Vehicle development begins with purified water, a non-reducing sweetener such as sorbitol solution or sucrose, and a preservative system when the container is a multi-dose format; preservative efficacy is verified by Ph. Eur. 5.1.3 or USP <51>. Sodium benzoate at 0.1% w/w is a typical preservative when the pH is below 5.0; above this pH its antimicrobial activity decreases. The pH is adjusted with dilute hydrochloric acid or sodium hydroxide, and the final specification includes pH, clarity, colour, assay, related substances, and microbial limits. Related substances are quantified by liquid chromatography using Ph. Eur. 2.2.29 or USP <621>. The solution is protected from light with amber glass or an opaque overwrap because the phenolic moiety is susceptible to photo-oxidation. Dissolved oxygen is reduced by nitrogen sparging during bulk preparation and filling; where permitted, an antioxidant such as sodium metabisulfite may be included, but patients with sulfite sensitivity require label identification. The oral liquid is filled by volumetric pump into bottles with tamper-evident closures, and dose delivery is confirmed with a calibrated dropper or measuring cup. Storage orientation and temperature are justified by ICH Q1A(R2) stability data, and the product must not be mixed with alkaline parenteral fluids or highly oxidising agents in a closed system.

Injectable Etilefrine HCl: Terminal Sterilization Versus Aseptic Filling

Injectable etilefrine HCl solutions are produced as sterile, isotonic parenterals, usually at a concentration of 10 mg/mL. The formulation contains water for injection, sodium chloride for osmolality adjustment, and may include an antioxidant such as sodium metabisulfite under a nitrogen overlay. The pH is optimised to maintain chemical stability and to avoid precipitation of the free base in the vial; pH specifications are established through forced degradation studies conducted under ICH Q1A(R2) and photostability under ICH Q1B. The primary packaging is Type I borosilicate glass vials with halobutyl rubber stoppers. Terminal sterilization by moist heat at 121°C for 15 min is preferred when the solution remains within the approved assay and related substance limits after autoclaving. If forced degradation data show that terminal heat exposure increases oxidative degradation beyond acceptance criteria, aseptic filtration through a 0.22 µm low-protein-binding filter is used. Aseptic filling is performed in EU GMP Annex 1 Grade A stations within Grade B background, with filtered air pressure differentials, fill volume checks, and sterile filter integrity tests before and after filling. Release tests include sterility per USP <71>, bacterial endotoxins per USP <85>, particulate matter per USP <788>, pH, osmolality, assay, and related substances. The following matrix summarises the process control differences between terminal sterilization and aseptic filling for this parenteral.

Container closure integrity for both sterilization routes is verified per USP <1207>, and the batch is not released until all compendial and in-process limits are satisfied.